Endothelin ETA receptor antagonism in cardiovascular disease

Area of Science:

• Cardiovascular Physiology
• Pharmacology

Background:

• The endothelin system, discovered in 1988, plays a role in cardiovascular regulation.
• Endothelin-1 (ET-1) influences vascular tone, proliferation, and inflammation via ETA and ETB receptors on smooth muscle and endothelial cells.

Purpose of the Study:

• To review the role of ET-1 in cardiovascular modulation.
• To explore the therapeutic potential of endothelin receptor antagonism in cardiovascular diseases.

Main Methods:

• Literature review of experimental and clinical studies.
• Analysis of endothelin receptor function and blockade effects.

Main Results:

• The ETA receptor is implicated in systemic hypertension, pulmonary arterial hypertension (PAH), dilated cardiomyopathy, and diabetic microvascular dysfunction.
• ETA receptor blockade demonstrates therapeutic promise for major cardiovascular pathologies.
• Simultaneous ETB receptor blockade may be detrimental, causing vasoconstriction and fluid retention.

Conclusions:

• Targeting the ETA receptor offers a promising therapeutic strategy for cardiovascular diseases.
• Selective ETA antagonism may be more beneficial than dual ETA/ETB blockade.